Pharmacodynamic Models for Discrete Data

Clinical outcomes are often described as events: death, stroke, epileptic seizure, multiple sclerosis lesions, recurrence of cancer, disease progression, pain, infection and bacterial/viral eradication, severe toxic adverse effect, resistance to treatment, etc. They may be quantified as time-to-event, counts of events per time interval (rates), their severity grade, or a combination of these. Such data are discrete and require specific modelling structures and methods. This article references the most common modelling approaches for categorical, count and time-to-event data, and reviews examples of such models applied in the analysis of pharmacodynamic data. Modelling is useful for identification of influential factors related to the clinical outcome, characterization and quantification of their impact, for making better informed predictions and clinical decisions, assessments of efficacy of therapeutic interventions, optimizing the individual treatments and drug development studies.

[1]  Gordon Graham,et al.  Determination of an Optimal Dosage Regimen Using a Bayesian Decision Analysis of Efficacy and Adverse Effect Data , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  R. Hamman,et al.  Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. , 2006, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[3]  Analysis of responses in migraine modelling using hidden Markov models , 2007, Statistics in medicine.

[4]  K. Blesch,et al.  Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. , 2003, British journal of clinical pharmacology.

[5]  Jerome J. Schentag,et al.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. , 1997, The Journal of antimicrobial chemotherapy.

[6]  Siv Jönsson,et al.  Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.

[8]  J Wakefield,et al.  Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores , 2001, Statistics in medicine.

[9]  Patrick J. Johnson,et al.  Modeling and Simulation of Sexual Activity Daily Diary Data of Patients with Female Sexual Arousal Disorder Treated with Sildenafil Citrate (Viagra®) , 2006, Pharmaceutical Research.

[10]  D. Hedeker,et al.  A Mixed-eeects Regression Model for Three-level Ordinal Response Data , 2022 .

[11]  John Eose,et al.  Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial , 2010, British Journal of Cancer.

[12]  Mats O. Karlsson,et al.  A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  M. Danhof,et al.  A model-based approach to treatment comparison in acute migraine. , 2006, British journal of clinical pharmacology.

[14]  E. Snoeck,et al.  Dose–response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures , 2007, Epilepsy Research.

[15]  Carmen Cadarso-Suárez,et al.  Multi-state models for the analysis of time-to-event data , 2009, Statistical methods in medical research.

[16]  Lewis B. Sheiner,et al.  A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron , 1999, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.

[18]  Meindert Danhof,et al.  A pharmacodynamic Markov mixed‐effect model for the effect of temazepam on sleep , 2000, Clinical pharmacology and therapeutics.

[19]  L B Sheiner,et al.  Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.

[20]  Andrew C. Hooker,et al.  Modeling Subpopulations with the $MIXTURE Subroutine in NONMEM: Finding the Individual Probability of Belonging to a Subpopulation for the Use in Model Analysis and Improved Decision Making , 2009, The AAPS Journal.

[21]  J. Hagenaars,et al.  Methods in Human Growth Research: Ordinal longitudinal data analysis , 2004 .

[22]  Brian Corrigan,et al.  Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures , 2003, Clinical pharmacology and therapeutics.

[23]  J. Verweij,et al.  Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.

[24]  J. Lindsey,et al.  Simple models for repeated ordinal responses with an application to a seasonal rhinitis clinical trial. , 1997, Statistics in medicine.

[25]  Naoki Ishiguro,et al.  A MULTICENTRE STUDY , 2010 .

[26]  L. Aarons,et al.  Methodological approaches to the population analysis of toxicity data. , 2001, Toxicology letters.

[27]  C. Veyrat‐Follet,et al.  Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization , 2000, Clinical pharmacology and therapeutics.

[28]  A. Agresti,et al.  Multinomial logit random effects models , 2001 .

[29]  Pascal Girard,et al.  Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data , 2011, Comput. Methods Programs Biomed..

[30]  Modeling and Simulation to Support Dose Selection and Clinical Development of SC‐75416, a Selective COX‐2 Inhibitor for the Treatment of Acute and Chronic Pain , 2008, Clinical pharmacology and therapeutics.

[31]  Lynn McFadyen,et al.  A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  M. Barras,et al.  Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. , 2009, British journal of clinical pharmacology.

[33]  L E Friberg,et al.  A Pharmacodynamic Markov Mixed‐Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis , 2009, Clinical pharmacology and therapeutics.

[34]  Mats O. Karlsson,et al.  Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models , 2011, Pharmaceutical Research.

[35]  Evaluation of Mixture Modeling with Count Data Using NONMEM , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  W. Weber,et al.  Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery , 2002, Clinical pharmacology and therapeutics.

[37]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[38]  I. Court-Fortune,et al.  Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. , 2008, Lung cancer.

[39]  L B Sheiner,et al.  A Markov mixed effect regression model for drug compliance. , 1998, Statistics in medicine.

[40]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[41]  Elisa Lee,et al.  Statistical Methods for Survival Data Analysis: Lee/Survival Data Analysis , 2003 .

[42]  P. Girard,et al.  Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease , 2007, Clinical pharmacokinetics.

[43]  F. Harrell,et al.  Partial Proportional Odds Models for Ordinal Response Variables , 1990 .

[44]  D. Mould,et al.  Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors , 2002, Clinical pharmacology and therapeutics.

[45]  A. Megens,et al.  Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  Adrian Dunne,et al.  Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .

[47]  Matts Kågedal,et al.  Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[48]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[49]  Mark E. Sale,et al.  A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[51]  C. Twelves,et al.  A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine , 2009, Clinical pharmacology and therapeutics.

[52]  Chuanpu Hu,et al.  Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[53]  I. Trocóniz,et al.  Population Pharmacokinetic/Pharmacodynamic Modelling of the Analgesic Effects of Tramadol in Pediatrics , 2006, Pharmaceutical Research.

[54]  R. Miller,et al.  Exposure‐response Analysis for Spontaneously Reported Dizziness in Pregabalin‐treated Patient With Generalized Anxiety Disorder , 2008, Clinical pharmacology and therapeutics.

[55]  M. Hutmacher,et al.  Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[56]  Mats O. Karlsson,et al.  Modelling overdispersion and Markovian features in count data , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[57]  A. Agresti,et al.  The analysis of ordered categorical data: An overview and a survey of recent developments , 2005 .

[58]  P. Girard,et al.  Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation , 2012, Cancer Chemotherapy and Pharmacology.

[59]  L. Aarons,et al.  Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements , 2009, Journal of biopharmaceutical statistics.

[60]  P. McCullagh Regression Models for Ordinal Data , 1980 .

[61]  J. Anderson,et al.  Regression, Discrimination and Measurement Models for Ordered Categorical Variables , 1981 .

[62]  P. Marcellin,et al.  Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C , 2005, Clinical pharmacokinetics.

[63]  A. Agresti Modelling ordered categorical data: recent advances and future challenges. , 1999, Statistics in medicine.

[64]  J. DeJongh,et al.  Population pharmacokinetic and pharmacodynamic modeling of propofol for long‐term sedation in critically ill patients: A comparison between propofol 6% and propofol 1% , 2002, Clinical pharmacology and therapeutics.

[65]  F. Raffi,et al.  Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults , 2007, Therapeutic drug monitoring.

[66]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.